Rajendra Kanneganti
Psychiatry · Detroit, MINPI 1851468441
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 411 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 411 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Supernus Pharmaceuticals, Inc.$1K
- Ironshore Pharmaceuticals Inc.$961
- Alkermes, Inc.$836
- Corium, LLC$811
- Sunovion Pharmaceuticals Inc.$578
- plus $3K from 21 others
What the payments were for
- Food & beverage$8,573100%
- Education$410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 54 | $1,141 |
| Supernus Pharmaceuticals, Inc. | 95 | $1,122 |
| Ironshore Pharmaceuticals Inc. | 41 | $961 |
| Alkermes, Inc. | 21 | $836 |
| Corium, LLC | 53 | $811 |
| Sunovion Pharmaceuticals Inc. | 32 | $578 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $473 |
| Neurocrine Biosciences, Inc. | 10 | $421 |
| Axsome Therapeutics, Inc. | 3 | $375 |
| E.r. Squibb & Sons, L.L.C. | 13 | $320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $196 |
| Johnson & Johnson | 11 | $192 |
| AbbVie(2 entities) | 4 | $179 |
| Lundbeck LLC | 10 | $176 |
| Tris Pharma Inc | 10 | $162 |
| Acadia Pharmaceuticals Inc | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 6 | $113 |
| Adlon Therapeutics L.p. | 5 | $91 |
| Validus Pharmaceuticals LLC | 2 | $67 |
| Shire North American Group Inc | 4 | $65 |
| Indivior Inc. | 2 | $56 |
| Noven Therapeutics, LLC | 3 | $47 |
| Vertical Pharmaceuticals, LLC | 2 | $35 |
| Neos Therapeutics, LP | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,614 in reported general payments places this provider in the 90th percentile of 1,166 psychiatry providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate ErQuetiapine Fumarate | 24 | $654 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $294 |
| Lithium Carbonate | 13 | $189 |
| Sertraline Hcl | 40 | $189 |
| Quetiapine Fumarate | 25 | $103 |
| Clonazepam | 13 | $41 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Detroit
- Andreas SidiropoulasDetroit$2.8M
- Arash JavanbakhtDetroit$102K
- Matcheri KeshavanDetroit$48K
- Gerald WinderDetroit$30K
- John HeadDetroit$28K
- David HarrisDetroit$11K
- Jennifer SharmaDetroit$10K
- Welton WashingtonYpsilanti$1.4M
- Joel YoungRochester Hills$1.1M
- Manzar RajputMonroe$612K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.